You just read:

ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumour Consortium for ICT-107 Phase 3 Registrational Trial in Glioblastoma

News provided by

ImmunoCellular Therapeutics, Ltd.

Dec 14, 2015, 06:00 ET